Apellis Pharmaceuticals (NASDAQ:APLS) Insider Mark Jeffrey Delong Sells 1,334 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Mark Jeffrey Delong sold 1,334 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $19.79, for a total transaction of $26,399.86. Following the completion of the sale, the insider directly owned 81,724 shares of the company’s stock, valued at approximately $1,617,317.96. The trade was a 1.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Mark Jeffrey Delong also recently made the following trade(s):

• On Tuesday, January 13th, Mark Jeffrey Delong sold 1,780 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $22.19, for a total transaction of $39,498.20.

Apellis Pharmaceuticals Price Performance

Shares of Apellis Pharmaceuticals stock opened at $20.95 on Thursday. The company has a 50-day simple moving average of $22.95 and a two-hundred day simple moving average of $23.50. Apellis Pharmaceuticals, Inc. has a twelve month low of $16.10 and a twelve month high of $31.17. The stock has a market capitalization of $2.65 billion, a price-to-earnings ratio of 67.58 and a beta of 0.31. The company has a quick ratio of 3.10, a current ratio of 3.54 and a debt-to-equity ratio of 0.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Thursday, October 30th. The company reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.64. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The business had revenue of $458.58 million during the quarter, compared to the consensus estimate of $364.58 million. During the same quarter in the previous year, the firm earned ($0.46) earnings per share. Apellis Pharmaceuticals’s revenue for the quarter was up 133.0% compared to the same quarter last year. Analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of hedge funds have recently bought and sold shares of APLS. Parallel Advisors LLC grew its position in shares of Apellis Pharmaceuticals by 80.0% during the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock valued at $33,000 after acquiring an additional 855 shares during the period. Jones Financial Companies Lllp grew its holdings in Apellis Pharmaceuticals by 206.8% during the third quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock valued at $46,000 after purchasing an additional 1,373 shares during the period. Osaic Holdings Inc. increased its position in Apellis Pharmaceuticals by 141.2% in the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock worth $47,000 after buying an additional 1,570 shares during the last quarter. Allworth Financial LP raised its stake in shares of Apellis Pharmaceuticals by 64.1% in the third quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after buying an additional 857 shares during the period. Finally, Quantbot Technologies LP purchased a new position in shares of Apellis Pharmaceuticals during the 3rd quarter valued at $64,000. 96.29% of the stock is owned by hedge funds and other institutional investors.

More Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS from Neutral to Buy, citing a stronger-than-expected launch trajectory for its newly approved kidney-disease therapy and assigning a $28 price target, which signals meaningful upside from current levels. Apellis upgraded at BofA on launch trajectory for kidney disease therapy
• Positive Sentiment: An analyst piece highlights early uptake of Empaveli (Apellis’s newly approved rare-kidney-disease treatment) and argues current Apellis valuation understates Empaveli’s revenue potential — a narrative that supports a re-rating if commercial momentum continues. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target from $29 to $26 but maintained an Overweight rating — a mixed signal that lowers upside expectations but keeps institutional support. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold on APLS, which is a neutral institutional stance and may limit upside from investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: Multiple senior insiders (including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and other officers) sold shares on Jan. 20 — a cluster of Form 4 filings that can weigh on sentiment even if transactions are routine diversification. See CEO filing here for details. CEO Cedric Francois Form 4

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on APLS. Robert W. Baird upped their price objective on Apellis Pharmaceuticals from $50.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. JPMorgan Chase & Co. dropped their price target on shares of Apellis Pharmaceuticals from $40.00 to $36.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. The Goldman Sachs Group reissued a “sell” rating and issued a $19.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, January 12th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Apellis Pharmaceuticals in a research report on Monday, December 29th. Finally, HC Wainwright reduced their price target on Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Twelve investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $33.53.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.